Why a Non-Metastatic Prostate Cancer Should Become a Castration Resistant Prostate Cancer?

Volume 4 - Issue 5

Francesco Carrozza¹* and Matteo Santoni²

Received: January 20, 2020;   Published: February 07, 2020

DOI: 10.32474/RRHOAJ.2020.04.000196

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

The issue of resistance to the “hormonal deprivation control” in Prostate Cancer (PC), is one of the most common and problematic aspects of this disease. It is well known how, under hormonal deprivation, the PC tends to increase over time its threshold of tolerability to ever lower levels of testosterone (usually produced by the cancer itself through paracrine or autocrine mechanisms). The hormone sensitivity (HS) period of PC lasts about 2 years; therefore, the disease subsequently develops increasingly effective mechanisms of resistance to androgen deprivation therapy (ADT), which will transform it into castration-resistant PC (CRPC).

Short Communication|